NOKOMIS, Fla.--(BUSINESS WIRE)--Since the new year began, Rainbow Coral Corp. (OTCBB: RBCC) has wasted no time in searching for new targets to add to its portfolio of projects for commercialization. Last week, the Company’s executive leadership accepted an invitation to tour a genome-mapping facility in Houston with which RBCC could soon partner. New healthcare innovations related to the human genome represent a target-rich area of interest for RBCC. The Texas company currently being reviewed performs tests to identify genetic markers in patients that can potentially boost or nullify the effects of certain medications. Such testing could dramatically change the way medications are prescribed, potentially fostering a significant reduction in global health care costs.
